A large body of experience has been compiled in different countries, documenting the efficacy of adenocorticotropic hormone (ACTH) for infantile spasms. This is important, because it may serve as a key for understanding this disorder, as well as for designing better medicines. However, significant discrepancies exist among studies originating in different countries regarding the relative efficacy of small or large ACTH doses.
Introduction
Around the world, clinicians use the adenocorticotropic hormone (ACTH) to treat West syndrome (WS). However, marked discrepancies exist in several aspects of this treatment. These may involve:
1. A potential biological difference of WS in different countries. 2. Potential differences in the definition of efficacy, including duration of treatment. 3. The type of hormonal preparations.
These issues are discussed below.
WS is not a homogenous entity
Distinct properties of infants who have WS together with tuberous sclerosis (TS), including their exquisite responsiveness to vigabatrin have been recognized. If genetic factors contribute to WS -even if the actual seizures are triggered by superimposed insults -could it be that the biology of WS differs around the world? At a minimum, genetically based differential responsiveness to low doses of ACTH may well explain the apparent differences between response to very low doses of ACTH in Japan and in the US.
How do we define efficacy?
Because WS is such a difficult disorder, even relatively moderate responses are considered a success. For example, a number of landmark studies considered response rates of 40-50% highly significant, and indeed they are [e.g. 1,2].
Prednisone and related steroids demonstrate this type of efficacy, as does vigabatrin in non-TS patients (US data) and topiramate [3] . For other agents, several studies report on efficacy rates of 11% (for B6, [4]) or 23% [5] . In contrast, others considered the response of 85-90% of infants as 'excellent efficacy' [6, 7] . Other difficulties in comparing efficacy are derived from often small numbers of patients (five per group, [8]) or from the occasional use of reduction E-mail address: tallie@uci.edu (T.Z. Baram).
